William Bruce Wong (William B Wong, William Wong)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 21

Top Topics

Glycemic Control

Metastatic Colorectal Cancer

Affordable Care Act

Top Venues

Cancer research communications

Future oncology (London, England)

Health affairs scholar

This page only lists publications with an associated author ORCID identifier.

Publications

Yiqing Zhao, Anastasios Dimou, Zachary C Fogarty, Jun Jiang, Hongfang Liu, William Bruce Wong, Chen Wang
Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels. Cancer research communications 4 (2) (2024)
Yiqing Zhao, Anastasios Dimou, Zachary C Fogarty, Jun Jiang, Hongfang Liu, William Bruce Wong, Chen Wang
Real-World Trends, Rural-Urban Differences and Socioeconomic Disparities in Utilization of Narrow vs. Broad Next-Generation Sequencing Panels. Cancer research communications (2024)
Yiqing Zhao, Anastasios Dimou, Zachary C Fogarty, Jun Jiang, Hongfang Liu, William Bruce Wong, Chen Wang
Real-World Trends, Rural-Urban Differences and Socioeconomic Disparities in Utilization of Narrow vs. Broad Next-Generation Sequencing Panels. Cancer research communications (2024)
Fariel LaMountain, Molly T Beinfeld, William Bruce Wong, Eunice Kim, James D Chambers
Biosimilar underutilization alone does not foretell a broken biologics market. Health affairs scholar 2 (7) (2024)
Yiqing Zhao, Anastasios Dimou, Zachary C Fogarty, Jun Jiang, Hongfang Liu, William Bruce Wong, Chen Wang
Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels. Cancer research communications 4 (2) (2024)
William Bruce Wong, Stacey Kowal, Tu My To, Achal Patel, David L Veenstra, Louis P Garrison, Meng Li
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations. Future oncology (London, England) (2024)
Yiqing Zhao, Anastasios Dimou, Zachary C Fogarty, Jun Jiang, Hongfang Liu, William Bruce Wong, Chen Wang
Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels. Cancer research communications 4 (2) (2024)
Fariel LaMountain, Molly T Beinfeld, William Bruce Wong, Eunice Kim, James D Chambers
Biosimilar underutilization alone does not foretell a broken biologics market. Health affairs scholar 2 (7) (2024)
William Bruce Wong, Stacey Kowal, Tu My To, Achal Patel, David L Veenstra, Louis P Garrison, Meng Li
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations. Future oncology (London, England) (2024)
William Bruce Wong, Stacey Kowal, Tu My To, Achal Patel, David L Veenstra, Louis P Garrison, Meng Li
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations. Future oncology (London, England) 20 (16) (2024)
Yiqing Zhao, Anastasios Dimou, Zachary C Fogarty, Jun Jiang, Hongfang Liu, William Bruce Wong, Chen Wang
Real-World Trends, Rural-Urban Differences and Socioeconomic Disparities in Utilization of Narrow vs. Broad Next-Generation Sequencing Panels. Cancer research communications (2024)
William Bruce Wong, Arpamas Seetasith, Anna Hung, Leah L Zullig
Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs. PloS one 18 (1) (2023)
William Bruce Wong, Danny Sheinson, Yutong Liu, Tu My To
Costs associated with the use of multigene panel tests in three solid tumor types and the impact on insurance premiums. Future oncology (London, England) (2023)
William Bruce Wong, Arpamas Seetasith, Anna Hung, Leah L Zullig
Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs. PloS one 18 (1) (2023)
William Bruce Wong, Arpamas Seetasith, Anna Hung, Leah L Zullig
Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs. PloS one 18 (1) (2023)
William Bruce Wong, Arpamas Seetasith, Anna Hung, Leah L Zullig
Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs. PloS one 18 (1) (2023)
William Bruce Wong, Arpamas Seetasith, Anna Hung, Leah L Zullig
Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs. PloS one 18 (1) (2023)
Woojung Lee, William Bruce Wong, Stacey Kowal, Louis P Garrison, David L Veenstra, Meng Li
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer. PharmacoEconomics 40 (6) (2022)
William Bruce Wong, Daniele Anina, Chia-Wei Lin, Devon V Adams
Alignment of health plan coverage policies for somatic multigene panel testing with clinical guidelines in select solid tumors. Personalized medicine 19 (3) (2022)
Robert C Doebele, Laura Perez, Huong Trinh, Michael Martinec, Reynaldo Martina, Todd Riehl, Matthew G Krebs, Neal J Meropol, William Bruce Wong, Gracy Crane
Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. Journal of comparative effectiveness research 10 (17) (2021)
Daniel M Sheinson, William Bruce Wong, Carlos Flores Avile, Sarika Ogale, Cary P Gross
Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing. JCO oncology practice 17 (11) (2021)